Suven Pharmaceuticals Ltd
NSE:SUVENPHAR
Suven Pharmaceuticals Ltd
NSE:SUVENPHAR
Price:
1 097
INR
3.12%
Market Closed
Market Cap:
₹419.7B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Suven Pharmaceuticals Ltd
NSE:SUVENPHAR
|
IN |
|
P
|
Palfinger AG
VSE:PAL
|
AT |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of SUVENPHAR.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
SUVENPHAR
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
SUVENPHAR Competitors Multiples
Suven Pharmaceuticals Ltd Competitors
Suven Pharmaceuticals Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Suven Pharmaceuticals Ltd
NSE:SUVENPHAR
|
419.7B INR | 40 | 150.3 | 112.5 | 133.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
900.7B USD | 13.8 | 43.6 | 29.4 | 31.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
581B USD | 6.2 | 21.7 | 15.1 | 18.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236B GBP | 5.3 | 30.6 | 16.9 | 23.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.2 | 11.4 | 12.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
304.8B USD | 4.7 | 16.7 | 10.3 | 12.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.9B CHF | 5.2 | 20.8 | 12.9 | 16.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.5 | 10.5 | 7.8 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.2B USD | 2.5 | 20.1 | 7.7 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119.2B USD | 2.5 | 16.9 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
